Meeting
2024 ASCO Genitourinary Cancers Symposium
Testosterone suppression and recovery in patients with advanced prostate cancer treated with intermittent androgen deprivation therapy (iADT) with relugolix.
Authors
Patrick Campbell
University of Utah Health, Salt Lake City, UT
Patrick Campbell , Georges Gebrael , Arshit Narang , Chadi Hage Chehade , Vinay Mathew Thomas , Gliceida Galarza Fortuna , Nicolas Sayegh , Nishita Tripathi , Clara Tandar , Emre Dal , Haoran Li , Umang Swami , Neeraj Agarwal , Benjamin L. Maughan
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Poster Session A: Prostate Cancer
Track
Prostate Cancer - Advanced,Prostate Cancer - Localized
Sub Track
Quality of Care/Quality Improvement and Real-World Evidence
Citation
J Clin Oncol 42, 2024 (suppl 4; abstr 70)
DOI
10.1200/JCO.2024.42.4_suppl.70
Abstract #
70
Poster Bd #
C5
Abstract Disclosures
Similar Posters
Poster
2022 ASCO Genitourinary Cancers Symposium
Impact of concomitant cardiovascular therapies on efficacy and safety of relugolix verus leuprolide in men with advanced prostate cancer: Subgroup analysis from the phase 3 HERO study.
First Author: Neal D. Shore
Poster
2024 ASCO Genitourinary Cancers Symposium
Real-world experience on tolerability and safety of relugolix combined with androgen signaling inhibitors in patients with advanced prostate cancer.
First Author: Jian Guan
Poster
2022 ASCO Annual Meeting
Efficacy and safety of relugolix in men with advanced prostate cancer based on baseline body mass index (BMI): A subgroup analysis from the randomized, phase 3 HERO study versus leuprolide (LEU).
First Author: Fred Saad
Poster
2022 ASCO Genitourinary Cancers Symposium
Testosterone recovery for relugolix versus leuprolide in men with advanced prostate cancer: Results from the phase 3 HERO study.
First Author: Ronald F. Tutrone